162 related articles for article (PubMed ID: 25834540)
1. Diagnostic utility of clinical and biochemical parameters in pancreatic head malignancy patients with normal carbohydrate antigen 19-9 levels.
Jin X; Wu Y
Afr Health Sci; 2015 Mar; 15(1):123-30. PubMed ID: 25834540
[TBL] [Abstract][Full Text] [Related]
2. Adjusting CA19-9 values to predict malignancy in obstructive jaundice: influence of bilirubin and C-reactive protein.
La Greca G; Sofia M; Lombardo R; Latteri S; Ricotta A; Puleo S; Russello D
World J Gastroenterol; 2012 Aug; 18(31):4150-5. PubMed ID: 22919247
[TBL] [Abstract][Full Text] [Related]
3. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
[TBL] [Abstract][Full Text] [Related]
4. Applicative Value of Serum CA19-9, CEA, CA125 and CA242 in Diagnosis and Prognosis for Patients with Pancreatic Cancer Treated by Concurrent Chemoradiotherapy.
Gu YL; Lan C; Pei H; Yang SN; Liu YF; Xiao LL
Asian Pac J Cancer Prev; 2015; 16(15):6569-73. PubMed ID: 26434876
[TBL] [Abstract][Full Text] [Related]
5. CA19-9 antigen levels can distinguish between benign and malignant pancreaticobiliary disease.
Morris-Stiff G; Teli M; Jardine N; Puntis MC
Hepatobiliary Pancreat Dis Int; 2009 Dec; 8(6):620-6. PubMed ID: 20007080
[TBL] [Abstract][Full Text] [Related]
6. Clinical values of CA19-9, CA125 and CEA in malignant obstructive jaundice.
Ng WW; Tong KJ; Tam TN; Lee SD
Zhonghua Yi Xue Za Zhi (Taipei); 1995 Jun; 55(6):438-46. PubMed ID: 7634181
[TBL] [Abstract][Full Text] [Related]
7. Preoperative carbohydrate antigen 19-9 is most predictive of malignancy in older jaundiced patients undergoing pancreatic resection.
Bloomston M; Bekaii-Saab TS; Kosuri K; Cowgill SM; Melvin WS; Ellison EC; Muscarella P
Pancreas; 2006 Oct; 33(3):246-9. PubMed ID: 17003645
[TBL] [Abstract][Full Text] [Related]
8. Periostin and CA242 as potential diagnostic serum biomarkers complementing CA19.9 in detecting pancreatic cancer.
Dong D; Jia L; Zhang L; Ma N; Zhang A; Zhou Y; Ren L
Cancer Sci; 2018 Sep; 109(9):2841-2851. PubMed ID: 29945294
[TBL] [Abstract][Full Text] [Related]
9. The clinical utility and limitations of serum carbohydrate antigen (CA19-9) as a diagnostic tool for pancreatic cancer and cholangiocarcinoma.
Singh S; Tang SJ; Sreenarasimhaiah J; Lara LF; Siddiqui A
Dig Dis Sci; 2011 Aug; 56(8):2491-6. PubMed ID: 21516323
[TBL] [Abstract][Full Text] [Related]
10. Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice.
Mann DV; Edwards R; Ho S; Lau WY; Glazer G
Eur J Surg Oncol; 2000 Aug; 26(5):474-9. PubMed ID: 11016469
[TBL] [Abstract][Full Text] [Related]
11. Pancreatic cancer and predictors of survival: comparing the CA 19-9/bilirubin ratio with the McGill Brisbane Symptom Score.
Dumitra S; Jamal MH; Aboukhalil J; Doi SA; Chaudhury P; Hassanain M; Metrakos PP; Barkun JS
HPB (Oxford); 2013 Dec; 15(12):1002-9. PubMed ID: 23521164
[TBL] [Abstract][Full Text] [Related]
12. [Prognostic value of carcinoembryonic antigen, alpha fetoprotein, carbohydrate antigen 125 and carbohydrate antigen 19-9 in gastroenteropancreatic neuroendocrine neoplasms].
Chen L; Zhang Y; Chen M; Chen J
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):1002-1008. PubMed ID: 28900990
[TBL] [Abstract][Full Text] [Related]
13. Predictors of malignancy in pancreatic head mass: a prospective study.
Sivaraman A; Muthukrishnan A; Boopathy Senguttvan N; Anil Suchak S; Kannan U
Pan Afr Med J; 2011; 9():30. PubMed ID: 22145063
[TBL] [Abstract][Full Text] [Related]
14. Clinical value of serum tumour markers CEA, CA 50 and CA 242 in the distinction between malignant versus benign diseases causing jaundice and cholestasis; results from a prospective study.
Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
Anticancer Res; 1992; 12(5):1687-93. PubMed ID: 1332581
[TBL] [Abstract][Full Text] [Related]
15. Prediction Model for Early-Stage Pancreatic Cancer Using Routinely Measured Blood Biomarkers.
Boyd LNC; Ali M; Comandatore A; Garajova I; Kam L; Puik JR; Fraga Rodrigues SM; Meijer LL; Le Large TYS; Besselink MG; Morelli L; Frampton A; van Laarhoven HWM; Giovannetti E; Kazemier G
JAMA Netw Open; 2023 Aug; 6(8):e2331197. PubMed ID: 37639271
[TBL] [Abstract][Full Text] [Related]
16. CA125 is superior to CA19-9 in predicting the resectability of pancreatic cancer.
Luo G; Xiao Z; Long J; Liu Z; Liu L; Liu C; Xu J; Ni Q; Yu X
J Gastrointest Surg; 2013 Dec; 17(12):2092-8. PubMed ID: 24146342
[TBL] [Abstract][Full Text] [Related]
17. Elevation of carbohydrate antigen 19.9 in benign hepatobiliary conditions and its correlation with serum bilirubin concentration.
Ong SL; Sachdeva A; Garcea G; Gravante G; Metcalfe MS; Lloyd DM; Berry DP; Dennison AR
Dig Dis Sci; 2008 Dec; 53(12):3213-7. PubMed ID: 18465243
[TBL] [Abstract][Full Text] [Related]
18. Improved Pancreatic Adenocarcinoma Diagnosis in Jaundiced and Non-Jaundiced Pancreatic Adenocarcinoma Patients through the Combination of Routine Clinical Markers Associated to Pancreatic Adenocarcinoma Pathophysiology.
Ferri MJ; Saez M; Figueras J; Fort E; Sabat M; López-Ben S; de Llorens R; Aleixandre RN; Peracaula R
PLoS One; 2016; 11(1):e0147214. PubMed ID: 26808421
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance and prognostic value of CA72-4 compared with CEA and CA19-9 in patients with gastric cancer.
Ychou M; Duffour J; Kramar A; Gourgou S; Grenier J
Dis Markers; 2000; 16(3-4):105-10. PubMed ID: 11381189
[TBL] [Abstract][Full Text] [Related]
20. Novel serum tumor marker, RCAS1, in pancreatic diseases.
Yamaguchi K; Enjoji M; Nakashima M; Nakamuta M; Watanabe T; Tanaka M
World J Gastroenterol; 2005 Sep; 11(33):5199-202. PubMed ID: 16127752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]